Stool frequency was assessed based on bowel movements recorded in the subject diaries 3 days a week. Additionally, the changes in fat-free mass were not significantly different between the treatment groups, indicating that the weight loss effect was primarily due to body fat reduction.

Seven subjects were excluded from the full analysis set (FAS) and the safety population as they attended only baseline visit and did not receive any investigational product. Through patented technologies, InQpharm has created a proprietary fibre complex with standardised lipophilic activity. The mean reduction in waist circumference was more pronounced in both IQP-AE-103 groups, compared with that in the placebo group at the end of the study. Therefore, in contrast to many available anti-obesity products that cause unpleasant and sometimes serious side effects, IQP-AE-103 could be considered as a safe, well-tolerated, and effective weight management agent.

SLIMFIT Appetite Reducer is an effective product for management of appetite, food cravings and compulsive eating habits. That way, you can safely reduce the dpi of images contained in your PDF and thus reduce the file size.

However, the vast majority of the currently available therapies are associated with unpleasant or even serious adverse effects. No significant differences in changes of feeling of fullness and food cravings between the study arms were observed.To evaluate a potential effect of IQP-AE-103 on food/energy intake, quantification of actual calorie intake by recording food consumption at an “ad libitum” lunch may be considered in future studies. G. Flamm, “Evaluation of safety of inulin and oligofructose as dietary fiber,” Regulatory Toxicology and Pharmacology, vol. In moderately obese subjects (BMI 30 to <35 kg/m 2), body weight was significantly reduced in comparison with placebo only in the high-dose IQP-AE-103 group (5.